Patient Characteristics
| Characteristic | Subgroup | Median | Range | No. of patients |
| Age at first PSMA RLT (y) | Overall | 72 | 50–88 | |
| Time interval from diagnosis to first PSMA RLT (y) | Overall | 7.5 | 2.5–14 | |
| Follow-up after final PSMA RLT (mo) | Overall | 15 | 6–28 | |
| Karnofsky Performance Status score (%) | Overall | 80 | 70–90 | |
| 70% | 23 | |||
| 80% | 14 | |||
| 90% | 19 | |||
| Pain (visual analog scale score) | Overall | 6 | ||
| <6 | 4 | |||
| ≥6 | 2 | |||
| Tumor stage | pT1 | 1 | ||
| pT2 | 13 | |||
| pT3 | 35 | |||
| pT4 | 7 | |||
| Previous therapies | Prostatectomy | 40 | ||
| External-beam radiation therapy | 47 | |||
| Chemotherapy | 25 | |||
| 223Ra-chloride | 1 | |||
| Hormone therapy | 56 | |||
| Luteinizing hormone–releasing hormone analogs | 56 | |||
| Cyproterone | 17 | |||
| Bicalutamide | 26 | |||
| Abiraterone | 21 | |||
| Enzalutamide | 11 |